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did not show signiﬁcant trend between responders and non
responders. Thus, sCD25 and TNFb can be potentially used as
biomarkers to predict response of cGvHD to ECP. Studies with
larger number of patients on ECP will be required to conﬁrm
these ﬁndings.429
Translation, Cross Cultural Adaptation and Validation of
the Chronic Graft-Versus-Host Disease (cGVHD) Symptom
Bother Scale in a Brazilian Population
Clarrissa V. de Souza 1, Afonso Vigorito 1, Eliana Miranda 1,
Celso Garcia Jr. 1, Vergilio A.R. Colturato 2, Marcos A. Mauad 2,
Maria Claudia R. Moreira 3, Luis Fernando S. Bouzas 4,
Simone Lermontov 5, Nelson Hamerschlak 6,
Morgani Rodrigues 7, J Carlos A. Barros 8, Ricardo Chiattone 9,
Stephanie J. Lee 10, Mary E.D. Flowers 11. 1 Hemocentro,
University of Campinas, Campinas, Brazil; 2Hospital Amaral
Carvalho - HAC, Jau, Brazil; 3 National Institute of Cancer INCA,
Rio de Janeiro, Brazil; 4 National Institute of Cancer INCA, Rio
De Janeiro, Brazil; 5 National Institute of Cancer INCA, Rio de
Janero, Brazil; 6 Hematology and Bone Marrow Transplantation
Dept, Hospital Israelita Albert Einstein, Brazil; 7 Hematology
and Bone Marrow Transplantation Dept, Hospital Israelita
Albert Einstein, Sao Paulo, Brazil; 8 Hematology, Santa Casa Sao
Paulo, Sao Paulo, Brazil; 9 Irmandade da Santa Casa de
Misericordia de Sao Paulo, Sao Paulo, Brazil; 10 Clinical
Transplant Research, Fred Hutchinson Cancer Research Center,
Seattle, WA; 11 Clinical Research, Fred Hutchinson Cancer
Research Center, Seattle, WA
The cGVHD Symptom Bother Scale, known as the Lee cGVHD
scale, is a patient reported questionnaire developed and
validated in English to measure symptoms and functional
losses in patients (pts.) with cGVHD. The Lee cGVHD scale
includes 30 questions with 7 subscales containing 2 to 7
items representing domains of skin, mouth, respiratory
system, gastrointestinal system, energy and psychological
status. The Lee cGVHD scale was translated into Portuguese
and validated according to the American Association of
Orthopedic Surgeons Outcome Committee guideline. 47 adult
pts with cGVHD diagnosed according to the 2005 NIH
consensus criteria were studied by the Brazil-Seattle cGVHD
Consortium between 2011 to 2012 at 5 centers. Median age
was 48 years (23-69) and 29 (61.7%) were male. All pts.
completed the Brazilian version of the Lee cGVHD ques-
tionnaire, the Medical Outcomes Study Short Form 36 (SF-
36) and the Functional Assessment of Chronic Illness Therapy
with Bone Marrow Transplant subscale (FACT-BMT). Overall
cGVHD severity was also assessed by pt. (0-3 scale) and by
physician (0-10 scale). Reliability was assessed using Cron-
bach's alpha and intraclass correlation coefﬁcients. Spear-
man's correlation coefﬁcient was used to measure constructOther Evaluations
Lee chronic GVHD Scale (0-100)y
Energy Skin Nutrition
SF-36
Physical Summary -0.49* -0.41* -0.43*
Emotional Summary -0.54* -0.32* -0.34*
FACT-BMT Summary 0.48* 0.40* 0.34*
GVHD severity rated by:
Physician 0.17 0.27 0.45*
Patient -0.04 0.15 0.25
* Correlation is signiﬁcant at the 0.05 level (2-tailed)
y Numbers represent Spearman’s correlation coefﬁcient: Very Low: 0.0< r  0.2validity. Results showed the reliability of the Lee cGVHD scale
was satisfactory (Cronbach's alpha 0.62-0.83). Correlation
coefﬁcients were moderate between similar domains of the
Lee cGVHD scale, SF-36, FACT-BMT and overall cGVHD
severity as rated by the physician but, correlation was low
between Lee cGVHD scale and overall cGVHD severity
assessed by patient (Table). The Brazilian Portuguese version
of the Lee cGVHD scale is reliable and easy to apply but
a larger cohort is needed to validate the instrument in this
population.430
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Background: Allogeneic hematopoietic stem cell trans-
plantation is a curative treatment for a number of hemato-
logical malignancies. Graft-versus-host disease (GVHD)
remains a leading cause of morbidity and mortality. Rabbit
anti-thymocyte globulin (ATG) is used to reduce the inci-
dence of GVHD. However, dosing regimens and schedules
vary.
Methods:We reviewed the medical records of 88 patients at
our institutionwho received ATG at either 4.5 or 6.0mg/kg, in
combination with tacrolimus and mycophenolate, prior to
allogeneic stem cell transplantation between 2009 and 2011.
ATG was administered over 3 days, ﬁnishing on day 0. We
retrospectively evaluated the prophylactic effect of each ATG
dosing regimen by measuring the incidence of severe (grade
III-IV) acute GVHD and acute GVHD-associated mortality. We
also measured relapse rate, overall survival (OS) and
progression-free survival (PFS) for both groups.
Results: A total of 52 patients who received ATG at 4.5mg/kg
(ATG1) were comparedwith 36 patients who received ATG at
6.0mg/kg (ATG2). The degree of HLA-mismatching was
greater in ATG2 (39.1% mismatched unrelated donors) as
compared to ATG1 (10% mismatched unrelated donors)
(P¼0.019) among 53 recipients from unrelated donors.
Median follow up for ATG1was 362 days, as compared to 512
days for ATG2. The cumulative incidence of grade III-IV acute
GVHD at day 100 was 13.9% and 6.5% in the ATG1 and ATG2
groups, respectively (P¼0.256). Speciﬁcally, 6 patients in
ATG1 developed grade IV GHVD, as compared to 0 patients in
ATG2. Acute GVHD-associated mortality was 7.7% and 0% in
ATG1 and ATG2, respectively (P¼0.141). All GVHD-associated
deaths occurred in patients with grade IV GVHD. The relapse
rates were comparable between ATG1 and ATG2 for bothLung Psych Eye Mouth Summary
-0.32* -0.51* -0.26 -0.35* -0.66*
-0.31* -0.70* -0.25 -0.27 -0.63*
0.18 0.49* 0.01 0.42* 0.48*
0.11 0.20 0.44* 0.27 0.51*
-0.07 0.06 27 0.21 0.25
, Low. 0.2 < r  0.4, Moderate 0.4 < r  0.6, High 0.6 < r
